Akari Therapeutics Statistics
Akari Therapeutics (CLA1) Stock Statistics & Valuation Metrics
Total Valuation
Akari Therapeutics has a market cap or net worth of EUR 11.50M. The enterprise value is EUR 11.29M.
- Market Cap
- EUR 11.50M
- Enterprise Value
- EUR 11.29M
Share Statistics
Akari Therapeutics has 2,285,165 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,285,165
- Owned by Insiders
- 17.16%
- Owned by Institutions
- 0.79%
Financial Efficiency
Akari Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -44.99%.
- Return on Equity (ROE)
- -0.61
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -44.99%
- Return on Capital Employed (ROCE)
- -0.49
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.88M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Akari Therapeutics is -0.00. Akari Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.74
- Price to FCF
- -1.64
- Price to Operating Cash Flow
- -1.28
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Akari Therapeutics had revenue of 0 and earned -17.30M in profits. Earnings per share was -20800.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -17.27M
- Pretax Income
- -18.30M
- Net Income
- -17.30M
- EBITDA
- -17.35M
- Earnings Per Share (EPS)
- -20800.00
Cash Flow
In the last 12 months, operating cash flow was -10.74M and capital expenditures -4, giving a free cash flow of -10.74M billion.
- Operating Cash Flow
- -10.74M
- Free Cash Flow
- -10.74M
- Free Cash Flow per Share
- -5.99
Dividends & Yields
Akari Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -63.37%
- Earnings Yield
- -234.17%
Stock Price Statistics
- Beta
- 1.35
- 52-Week Price Change
- -99.67%
- 50-Day Moving Average
- 0.06
- 200-Day Moving Average
- 0.97
- Relative Strength Index (RSI)
- 33.83
- Average Volume (3m)
- ―
Important Dates
Akari Therapeutics upcoming earnings date is Apr 21, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Apr 21, 2027
- Ex-Dividend Date
- ―
Financial Position
Akari Therapeutics as a current ratio of 0.44, with Debt / Equity ratio of 2.66%
- Current Ratio
- 0.44
- Quick Ratio
- 0.44
- Debt to Market Cap
- 3.10
- Net Debt to EBITDA
- 0.26
- Interest Coverage Ratio
- -18.20
Taxes
In the past 12 months, Akari Therapeutics has paid -1.00M in taxes.
- Income Tax
- -1.00M
- Effective Tax Rate
- 0.05
Enterprise Valuation
Akari Therapeutics EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.93.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.31
- EV to Free Cash Flow
- -0.93
- EV to Operating Cash Flow
- -0.93
Balance Sheet
Akari Therapeutics has EUR 7.69M in cash and marketable securities with EUR 693.00K in debt, giving a net cash position of EUR 7.00M billion.
- Cash & Marketable Securities
- EUR 7.69M
- Total Debt
- EUR 693.00K
- Net Cash
- EUR 7.00M
- Net Cash Per Share
- EUR 3.06
- Tangible Book Value Per Share
- -EUR 6.53
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Akari Therapeutics is EUR 22.87, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 22.87
- Price Target Upside
- 37389.34% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
